Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 33

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 33
---
| ✓          | Independent compensation consultant engaged by the Compensation Committee                                                              |
| ✓          | 100% independent directors on the Compensation Committee                                                                               |
| ✓          | No perquisites                                                                                                                         |

| WHAT WE DON’T DO |                                                                                                                        |
| ×                | No gross-ups for change of control related excise tax payments                                                         |
| ×                | No short sales, hedging, or transactions in derivative securities relating to our common stock                         |
| ×                | No strict benchmarking of Named Executive Officer compensation to a specific percentile of our compensation peer group |
| ×                | No pension benefits                                                                                                    |
| ×                | No dividend payments on unvested awards                                                                                |
| ×                | No ‘repricing’ of out-of-the-money stock options without shareholder approval                                          |
| ×                | No incentivizing unnecessary or excessive risk taking                                                                  |
| ×                | No employment agreements with Named Executive Officers that provide for a guaranteed term of employment                |

24

Say-On-Pay Vote

At our 2024 Annual Meeting, we held a Say-on-Pay (as defined below) vote on the compensation of our Named Executive Officers for fiscal 2023, which received the support of approximately 83% of the votes cast. This was lower than the Say-on-Pay vote support of approximately 98% of the votes cast at our 2023 Annual Meeting for the compensation of our Named Executive Officers for fiscal 2022. The Compensation Committee and our full Board took the Say-on-Pay vote outcome seriously when determining compensation for our Named Executive Officers in fiscal 2024.

Fiscal 2024 Named Executive Officer Compensation Program

Principles

The objectives of our Named Executive Officer compensation program are to:

Align the interests of Named Executive Officers with the long-term success of the business, our shareholders, and other stakeholders

Attract, develop, retain, and motivate Named Executive Officers to drive our business and financial performance

Link a significant amount of Named Executive Officer compensation to achievement of pre-established financial metrics and business goals that are directly tied to our overall business strategy

In evaluating the competitiveness of our Named Executive Officer compensation program, we compare it against the programs of peers in related industries at a similar stage of development and comparable financial profile. We also evaluate broader size-appropriate comparisons within the biotechnology and pharmaceutical industries. More information about our use of peer group data is provided below. Our compensation philosophy also recognizes the need for flexibility based on experience, scope of position, critical skills, and individual/corporate performance. We consider